Sublingual semaglutide is a GLP‑1 receptor agonist formulated to dissolve under the tongue, bypassing the GI tract’s first‑pass metabolism that can diminish tablet potency.

‍

Once absorbed, it mimics the natural hormone GLP‑1 released after you eat, triggering three weight‑friendly actions:

(1) slower gastric emptying—you feel full longer;

(2) reduced hunger signals in the hypothalamus;  

(3) improved insulin sensitivity, which curbs fat storage.

‍

Clinical data on injectable semaglutide shows average losses of 15 % of body weight at 68 weeks; early pilot studies on sublingual forms suggest similar pharmacokinetics when properly compounded, though large phase‑3 trials are ongoing. Most patients notice appetite reduction in week 1‑2, with measurable weight loss by week 4‑6 when paired with a modest calorie deficit.

‍

Common side‑effects (nausea, mild reflux) usually fade in two weeks and can be minimized by starting at a low micro‑dose and titrating every 4 weeks under provider supervision. Because sublingual semaglutide is compounded, it’s not yet FDA‑approved; we work only with 503A/503B‑certified pharmacies to ensure sterility and potency.